2024 Nasdaq rxrx - Over the past 3 months, 6 analysts have published their opinion on Recursion Pharmaceuticals (NASDAQ:RXRX) stock. These analysts are typically employed by large Wall Street banks and tasked with ...

 
Stock Recursion Pharmaceuticals, Inc. - Nasdaq. Recursion Pharmaceuticals, Inc. (RXRX.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and …. Nasdaq rxrx

Nasdaq Composite Stock Market Premium Services. Stock Advisor. Our Flagship Service. Return. 524%. S&P Return. 133%. Rule Breakers. ... (RXRX 1.18%), an innovative biotech. The company's shares ...The US$14.13 analyst price target for RXRX is 3.5% less than our estimate of fair value Does the July share price for Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ) reflect what it's really worth?Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Recursion Pharmaceuticals (NASDAQ:RXRX) recently gapped higher after receiving a $50 million investment from AI powerhouse Nvidia (NASDAQ:NVDA).With that, Recursion will use NVDA technology to ...RXRX POWR Grades. RXRX scores best on the Growth dimension, with a Growth rank ahead of 20.42% of US stocks. ... (NASDAQ:RXRX), sold 18,000 shares of the company on November 15, 2023. Yahoo | November 18, 2023. Insider Sell: CFO Michael Secora Offloads 50,000 Shares of Recursion Pharmaceuticals Inc (RXRX)$6.92 0.14 [2.06%] Last update: 10:53AM (Delayed 15-Minutes) Get Real Time Here $6.85 -0.0700 [-1.01%] Profile News Analyst Ratings Guidance Dividends …Recursion Pharmaceuticals (NASDAQ:RXRX) - the subject of this analysis - IPOd in April 2021, issuing 27.88m shares at a price of $18 per share, and raising >$500m - making it the sixth largest ...#3 Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) Sector: Healthcare | Biotechnology. Reason: Falling Wedge Pattern Breakout. A falling wedge pattern is formed by joining two downward-sloping, converging trendlines having a contracting range. The pattern appears to be wide at the top and continues to contract as prices fall.Recursion Pharmaceuticals Inc (NASDAQ:RXRX). 7.38. Delayed Data. As of Dec 01. +0.53 / +7.74%. Today's Change. 4.54. Today|||52-Week Range. 16.75. -4.28%. Year- ...Fiscal Q3 2023 ended 9/30/23. Get the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed...About Recursion Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets.Average portfolio weight of all funds dedicated to RXRX is 0.77%, an increase of 46.27%. Total shares owned by institutions increased in the last three months by 18.96% to 141,638K shares.12 Tem 2023 ... Confirming the ongoing fervor for all things artificial intelligence (AI), shares of biotechnology firm Recursion Pharmaceuticals (NASDAQ:RXRX) ...Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) institutional owners may be pleased with recent gains after 14% loss over the past year finance.yahoo.com - August 24 at 9:26 AM: Connor Clark & Lunn Investment Management Ltd. Buys 83,879 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) marketbeat.com - August 22 at 5:37 AMRecursion Pharmaceuticals (NASDAQ:RXRX) has witnessed quite a roller-coaster year. A resounding investment of $50 million from tech titan Nvidia (NASDAQ:NVDA) in July rocketed its shares.If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...Nov 15, 2023 · AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed by famous stock picker Cathie Wood, bought ~3.8M of ... Recursion is forging key relationships with powerful collaborators. The young biotech's valuation is also looking a lot better now. However, its finances are nowhere near breakeven yet. NASDAQ: RXRX. Recursion Pharmaceuticals. Market Cap. $1B. Today's Change. (13.00%) $0.68.Mar 28, 2023 · Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Revenue Growth YOY: 291.46% Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotechnology company based in the United States. The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Nov 15, 2023 · AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed by famous stock picker Cathie Wood, bought ~3.8M of ... Find the latest Earnings Report Date for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.SALT LAKE CITY, Aug. 18, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...Nov 15, 2023 · AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed by famous stock picker Cathie Wood, bought ~3.8M of ... SALT LAKE CITY, July 12, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry ...Recursion Pharmaceuticals Inc. Class A (RXRX) Share Price. NASDAQ. $7.05. As on 17-Nov-2023 16:06 EST. up-down-arrow $0.38 • 5.70%. 1D 1M 3M 1Y All Custom. Prev ...Recursion Pharmaceuticals (NASDAQ:RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s stock ...Dec 1, 2023 · Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) institutional owners may be pleased with recent gains after 14% loss over the past year finance.yahoo.com - August 24 at 9:26 AM: Connor Clark & Lunn Investment Management Ltd. Buys 83,879 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) marketbeat.com - August 22 at 5:37 AM (NASDAQ:RXRX), which I spoke about on Aug. 8. At the time, Nvidia (NASDAQ:NVDA) had just investing $50 million in the company to help it create new AI models, and software to create new drug ...Export data to Excel for your own analysis. Start Your 30-Day Free Trial. RXRX's current price target is $11.20. Learn why top analysts are making this stock …Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Lexicon Pharmaceuticals, Inc. Common Stock (LXRX) Pre-Market Stock Quotes ...12 Tem 2023 ... SALT LAKE CITY, TORONTO and MONTRÉAL, July 12, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company ...Nov 30, 2023 · Stock analysis for Recursion Pharmaceuticals Inc (RXRX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Oct 11, 2022 · Recursion Pharmaceuticals has a market capitalisation of US$1.9b and burnt through US$113m last year, which is 6.0% of the company's market value. Given that is a rather small percentage, it would ... Nov 18, 2023 · Of the 22 guru strategies we follow, RXRX rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that have ... SALT LAKE CITY, May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has ...Pre-Market Quotes Nasdaq-100 Ownership Search News + Insights Solutions Recursion Pharmaceuticals, Inc. Class A Common Stock P/E & PEG Ratios …Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Revenue Growth YOY: 291.46% Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotechnology company based in the United States.Or, we can look back at Recursion Pharmaceuticals. (NASDAQ:RXRX), which I spoke about on Aug. 8.At the time, Nvidia (NASDAQ:NVDA) had just investing $50 million in the company to help it create ...4. Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best and most notable AI healthcare stocks to buy. The Utah-based Recursion ...Based on analysts offering 12 month price targets for RXRX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . On May 8, Recursion Pharmaceuticals (RXRX 7.88%) announced that it was going to buy a pair of AI-enabled drug discovery biotechs, Cyclica and Valence, for a total of $87.5 million -- paid in stock.Mar 28, 2023 · Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Revenue Growth YOY: 291.46% Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotechnology company based in the United States. Nov 13, 2023 · The latest price target for . Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by JP Morgan on November 13, 2023. The analyst firm set a price target for $10.00 expecting RXRX to rise to ... Nasdaq Composite Stock Market Premium Services. Stock Advisor. Our Flagship Service. Return. 524%. S&P Return. 133%. Rule Breakers. ... (RXRX 1.18%), an innovative biotech. The company's shares ...RXRX: Recursion Pharmaceuticals Inc Stock Price Quote - NASDAQ GS - Bloomberg Subscribe S&P 500 4,556.62 +0.41% Nasdaq 14,265.86 +0.46% Crude Oil …Find the latest Earnings Report Date for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Current. -$0.35. 1 Month Ago. -$0.35. 3 Months Ago. -$0.32. Recursion Pharmaceuticals Inc. analyst estimates, including RXRX earnings per share estimates and analyst recommendations.Find the latest historical data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...On October 25, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) announced that it has entered into a stock purchase agreement for the sale of approximately 15.3 million units of its common stock in a ...Mar 28, 2023 · Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Revenue Growth YOY: 291.46% Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotechnology company based in the United States. Jul 6, 2023 · Average portfolio weight of all funds dedicated to RXRX is 0.48%, a decrease of 14.38%. Total shares owned by institutions decreased in the last three months by 7.71% to 130,292K shares. Get Recursion Pharmaceuticals Inc (RXRX.O) real-time stock quotes, news, price ... Nasdaq leads Wall St to higher close as CPI report lifts sentiment. July 12 ...Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has completed the Phase 1 study for REC-3964 in healthy ...Nov 22, 2023 · Nasdaq Composite Stock Market Premium Services. Stock Advisor. Our Flagship Service. Return. 524%. S&P Return. 133%. Rule Breakers. ... (RXRX 1.18%), an innovative biotech. The company's shares ... Find the latest Earnings Report Date for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.On October 25, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) announced that it has entered into a stock purchase agreement for the sale of approximately 15.3 million units of its common stock in a ...Nov 26, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (0.43%) $0.03. Current Price. $7.05. ... (RXRX 0.43%) that aims to use artificial intelligence (AI) and petabytes of data as ... 4. Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best and most notable AI healthcare stocks to buy. The Utah-based Recursion ...Welcome to Recursion: The Future of TechBio. Decoding Biology To Radically Improve Lives. Explore Our Story: We are leveraging new technology to create virtuous cycles of learning around datasets to build a next-generation biopharmaceutical company. It’s complex biology, decoded. Recursion Pharmaceuticals Stock forecast & analyst price target predictions based on 5 analysts offering 12-months price targets for RXRX in the last 3 months.SALT LAKE CITY, Aug. 18, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it recently received a Prime Rating for ESG performance from the industry-renowned Institutional Shareholder Services (ISS), which is the first time …Yet, risky stocks can also often offer attractive upside potential. Let's look at two examples: Recursion Pharmaceuticals ( RXRX 4.40%) and Madrigal Pharmaceuticals ( MDGL 1.83%). These two ...Recursion Pharmaceuticals (NASDAQ:RXRX) was a new buy in the portfolio last week. This is a clinical-stage biotechnology company that combines experimental biology, bioinformatics, and artificial ...RXRX.O. Official Data Partner. Latest Trade. trading higher 7.14 USD. Change 0.12 % Change + 1.71% Positive ... Nasdaq leads Wall St to higher close as CPI report lifts sentiment July 12, 2023.Nov 18, 2023 · Of the 22 guru strategies we follow, RXRX rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that have ... Nov 28, 2023 · Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information. Instantly RXRX has showed a red trend with a performance of -4.81% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 7.23 on Monday, 11/27/23 increased the stock’s daily price by 9.68%. The Dow Jones Industrial Average paced gains with a jump of nearly 1.5%, or more than 500 points, reaching a new closing high for 2023. The S&P 500 popped nearly 0.4%, reversing earlier losses ...Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has increased by 1.33 compared to its previous closing price of 6.78. However, the company has seen a 3.00% increase in its stock price over the last five trading sessions. The Motley Fool reported 2023-11-26 that Nvidia will help Recursion build a massive supercomputer. This …On October 25, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) announced that it has entered into a stock purchase agreement for the sale of approximately 15.3 million units of its common stock in a ...This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $35.00 ,the lowest forecast is $9.00. The …Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...JPMorgan Trims Price Target on Recursion Pharmaceuticals to $10 From $11, Maintains Neutral Rating. Nov. 13. MT. Needham Adjusts Recursion Pharmaceuticals Price Target to $15 From $17, Maintains Buy Rating. Nov. 10. MT. Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September …Nov 28, 2023 · Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information. Instantly RXRX has showed a red trend with a performance of -4.81% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 7.23 on Monday, 11/27/23 increased the stock’s daily price by 9.68%. Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Revenue Growth YOY: 291.46% Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotechnology company based in the United States.Recursion Pharmaceuticals has a market capitalisation of US$1.9b and burnt through US$113m last year, which is 6.0% of the company's market value. Given that is a rather small percentage, it would ...Nasdaq rxrx

Financial Performance. In 2022, RXRX's revenue was $39.84 million, an increase of 291.46% compared to the previous year's $10.18 million. Losses were -$239.48 million, 28.4% more than in 2021. Financial Statements.. Nasdaq rxrx

nasdaq rxrx

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Fintel reports that on July 12, 2023, Needham reiterated coverage of Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) with a Buy recommendation.. Analyst Price Forecast Suggests 117.07% Upside. As of ...Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s ...Earnings for Recursion Pharmaceuticals are expected to decrease in the coming year, from ($1.67) to ($1.91) per share. Recursion Pharmaceuticals has not …Discovering new drugs is no easy task, and one young company that aims to help in that process is Recursion Pharmaceuticals (NASDAQ: RXRX). Though it still hasn't brought a product to market just ...Stock Recursion Pharmaceuticals, Inc. - Nasdaq. Recursion Pharmaceuticals, Inc. (RXRX.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and …Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Jul 13, 2023 · Recursion Pharmaceuticals RXRX announced a significant investment worth $50 million from NVIDIA Corporation NVDA, a renowned technology company specializing in accelerated computing. The Dow Jones Industrial Average paced gains with a jump of nearly 1.5%, or more than 500 points, reaching a new closing high for 2023. The S&P 500 popped nearly 0.4%, reversing earlier losses ...If you're a biotech investor, you've probably heard of both Recursion Pharmaceuticals (NASDAQ: RXRX) and CRISPR Therapeutics, (NASDAQ: CRSP) two of the most followed biotechs this year. Both ...A lot of healthcare companies are seeking to brandish their AI bonafides, but Recursion Pharmaceuticals (RXRX 7.88%), and GE Healthcare Technologies (GEHC 1.39%) are already using AI to boost ...15 Kas 2023 ... ... (NASDAQ: RXRX), joins to discuss her company's recent performance, outlook for the biopharma space and its new notable investor, Cathie Wood ...SALT LAKE CITY, May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Netflix Inc (NASDAQ:NFLX): Bought 2,490 shares of the movie streaming company, representing about 0.199% of the ETF. Netflix stock closed 1.45% higher at $554.44 on Monday. It has a 52-week high ...5 Eki 2023 ... The average one-year price target for Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) has been revised to 17.17 / share.NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ... Check out our RXRX stock analysis, current RXRX quote, charts, and historical prices for Recursion Pharmaceuticals Inc Cl A stock. ... (NASDAQ:RXRX) From Seeking Alpha Oct 19, 2023 Royalty Pharma ...For a biotech like Recursion Pharmaceuticals (RXRX 0.43%) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a key ...Find the latest Insider Activity data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the top stock picks of Samsara BioCapital along with IVERIC bio, Inc. (NASDAQ:ISEE), Sutro Biopharma, Inc. (NASDAQ:STRO) and Forma ...Price. %Change. RXRX. 6.11. Trade stocks. You can practice and explore trading RXRX stock methods without spending real money on the virtual paper trading platform. Webull offers RXRX Ent Holdg (RXRX) historical stock prices, in-depth market analysis, NASDAQ: RXRX real-time stock quote data, in-depth charts, free RXRX options chain data, and a ... Find the latest historical data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.TORONTO, June 26, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today celebrated the opening of its ...Published: Nov 02, 2023. SALT LAKE CITY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conference: Jefferies London Healthcare Conference – November 14-16, 2023.Nov 9, 2023 · About RecursionRecursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a ... The Dow Jones Industrial Average paced gains with a jump of nearly 1.5%, or more than 500 points, reaching a new closing high for 2023. The S&P 500 popped nearly 0.4%, reversing earlier losses ...31 Eki 2023 ... Discovering new drugs is no easy task, and one young company that aims to help in that process is Recursion Pharmaceuticals (NASDAQ: RXRX).Recursion Pharmaceuticals has a market capitalisation of US$1.9b and burnt through US$113m last year, which is 6.0% of the company's market value. Given that is a rather small percentage, it would ...Nov 30, 2023 · Recursion Pharmaceuticals (NASDAQ:RXRX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both small-cap medical companies, but which is the better stock?We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment, valuation and community ranking. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Lexicon Pharmaceuticals, Inc. Common Stock (LXRX) Pre-Market Stock Quotes ...Webull offers RXRX Ent Holdg (RXRX) historical stock prices, in-depth market analysis, NASDAQ: RXRX real-time stock quote data, in-depth charts, free RXRX options chain data, and a fully built financial calendar to help you invest smart. Buy RXRX stock at Webull.Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.2,015.20 +2.80(+0.14%) Advertisement Recursion Pharmaceuticals, Inc. (RXRX) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 6.53 -0.33 (-4.81%) At close: 04:00PM EST 6.65... Financial Performance. In 2022, RXRX's revenue was $39.84 million, an increase of 291.46% compared to the previous year's $10.18 million. Losses were -$239.48 million, 28.4% more than in 2021. Financial Statements.Jul 12, 2023 · RXRX.O. Official Data Partner. Latest Trade. trading higher 7.14 USD. Change 0.12 % Change + 1.71% Positive ... Nasdaq leads Wall St to higher close as CPI report lifts sentiment July 12, 2023. Track Recursion Pharmaceuticals Inc - Ordinary Shares - Class A (RXRX) Stock Price, Quote, latest community messages, chart, news and other stock related ...Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global …Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the top stock picks of Samsara BioCapital along with IVERIC bio, Inc. (NASDAQ:ISEE), Sutro Biopharma, Inc. (NASDAQ:STRO) and Forma ...Find the latest quotes for Vanguard S&P 500 ETF (VOO) as well as ETF details, charts and news at Nasdaq.com.Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.The latest price target for . Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by JP Morgan on November 13, 2023. The analyst firm set a price target for $10.00 expecting RXRX to rise to ...Nov 24, 2023 · The average twelve-month price prediction for Recursion Pharmaceuticals is $11.20 with a high price target of $15.00 and a low price target of $8.00. Learn more on RXRX's analyst rating history. Do Wall Street analysts like Recursion Pharmaceuticals more than its competitors? #3 Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) Sector: Healthcare | Biotechnology. Reason: Falling Wedge Pattern Breakout. A falling wedge pattern is formed by joining two downward-sloping, converging trendlines having a contracting range. The pattern appears to be wide at the top and continues to contract as prices fall.NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ...Feb 28, 2023 · Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.38 per share a year ago. Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.38 per share a year ago.Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...Over the past 3 months, 6 analysts have published their opinion on Recursion Pharmaceuticals (NASDAQ:RXRX) stock. These analysts are typically employed by large Wall Street banks and tasked with ...After announcing that it would get a $50 million investment from NVIDIA ( NVDA 0.45%) on July 12, Recursion Pharmaceuticals ( RXRX 10.49%) saw its stock blast off, rising 87% over the following ...Find the latest Earnings Report Date for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Recursion Pharmaceuticals (NASDAQ: RXRX) hit headlines hard earlier in the year as artificial intelligence giant Nvidia announced a $50 million direct investment in the biotech stock.A lot of healthcare companies are seeking to brandish their AI bonafides, but Recursion Pharmaceuticals (RXRX 7.88%), and GE Healthcare Technologies (GEHC 1.39%) are already using AI to boost ...Earnings for Recursion Pharmaceuticals are expected to decrease in the coming year, from ($1.67) to ($1.91) per share. Recursion Pharmaceuticals has not …It has been a tumultuous year for the clinical-stage biotech Recursion Pharmaceuticals ( RXRX -2.84%). Earlier this year, the company's shares skyrocketed after it announced a partnership with the ...Nov 30, 2023 · Stock analysis for Recursion Pharmaceuticals Inc (RXRX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. That’s as shares of Recursion Pharmaceuticals (NASDAQ:RXRX) are exploding higher on the day. In fact, RXRX stock is currently up about 17% so far in the session.The average twelve-month price prediction for Recursion Pharmaceuticals is $11.20 with a high price target of $15.00 and a low price target of $8.00. Learn more on RXRX's analyst rating history. Do Wall Street analysts like Recursion Pharmaceuticals more than its competitors?SALT LAKE CITY, Sept. 13, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the initiation ...MarketWatch IBD Sign In Recursion Pharmaceuticals Inc. RXRX (U.S.: Nasdaq) Overview News Recursion Pharmaceuticals Inc. No significant news for in the …Sep 14, 2023 · Recursion Pharmaceuticals (NASDAQ:RXRX) was a new buy in the portfolio last week. This is a clinical-stage biotechnology company that combines experimental biology, bioinformatics, and artificial ... SALT LAKE CITY, June 20, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the initiation ...It plans to list on the Nasdaq under the symbol RXRX. Recursion Pharmaceuticals filed confidentially on January 26, 2021. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink and Allen ...12 Tem 2023 ... Shares of TechBio firm Recursion (NASDAQ:RXRX), which is working on decoding biology to revolutionize drug discovery, spiked at the time of ...Scores. RXRX has an Altman Z-Score of 1.67 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Recursion Pharmaceuticals, Inc. (RXRX) stock, including valuation metrics, financial numbers, share information and more.It plans to list on the Nasdaq under the symbol RXRX. Recursion Pharmaceuticals filed confidentially on January 26, 2021. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink and Allen ...Average portfolio weight of all funds dedicated to RXRX is 0.77%, an increase of 46.27%. Total shares owned by institutions increased in the last three months by 18.96% to 141,638K shares.Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. For a biotech like Recursion Pharmaceuticals (NASDAQ: RXRX) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a ...Real time Recursion Pharmaceuticals (RXRX) stock price quote, stock graph, news & analysis.Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was incorporated in 2013 and is headquartered in Salt Lake City, Utah. It operates as a clinical-stage biotechnology company, utilizing biology, ...That’s as shares of Recursion Pharmaceuticals RXRX are exploding higher on the day. In fact, RXRX stock is currently up about 17% so far in the session. Butterfly with parabolic D leg action. This looks like classic D leg stuff. All parabolic action, few pullbacks and getting a lot of public attention. Based on analysts offering 12 month price targets for RXRX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Find the latest Insider Activity data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. . Chase robo advisor